Literature DB >> 21463272

The core Dravet syndrome phenotype.

Charlotte Dravet1.   

Abstract

Dravet syndrome was described in 1978 by Dravet (1978) under the name of severe myoclonic epilepsy in infancy (SMEI). The characteristics of the syndrome were confirmed and further delineated by other authors over the years. According to the semiologic features, two forms have been individualized: (1) the typical, core, SMEI; and (2) the borderline form, SMEIB, in which the myoclonic component is absent or subtle. Clinical manifestations at the onset, at the steady state, and during the course of the disease are analyzed in detail for the typical Dravet syndrome, and the differential diagnosis is discussed. Onset in the first year of life by febrile or afebrile clonic and tonic-clonic, generalized, and unilateral seizures, often prolonged, in an apparently normal infant is the first symptom, suggesting the diagnosis. Later on, multiple seizure types, mainly myoclonic, atypical absences, and focal seizures appear, as well as a slowing of developmental and cognitive skills, and the appearance of behavioral disorders. Mutation screening for the SCN1A gene confirms the diagnosis in 70-80% of patients. All seizure types are pharmacoresistent, but a trend toward less severe epilepsy and cognitive impairment is usually observed after the age of 5 years. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463272     DOI: 10.1111/j.1528-1167.2011.02994.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  149 in total

Review 1.  SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome.

Authors:  Alex C Bender; Richard P Morse; Rod C Scott; Gregory L Holmes; Pierre-Pascal Lenck-Santini
Journal:  Epilepsy Behav       Date:  2012-02-16       Impact factor: 2.937

2.  Electrophysiological Alterations of Pyramidal Cells and Interneurons of the CA1 Region of the Hippocampus in a Novel Mouse Model of Dravet Syndrome.

Authors:  David A Dyment; Sarah C Schock; Kristen Deloughery; Minh Hieu Tran; Kerstin Ure; Lauryl M J Nutter; Amie Creighton; Julie Yuan; Umberto Banderali; Tanya Comas; Ewa Baumann; Anna Jezierski; Kym M Boycott; Alex E Mackenzie; Marzia Martina
Journal:  Genetics       Date:  2020-06-17       Impact factor: 4.562

3.  Azithromycin Causes a Novel Proarrhythmic Syndrome.

Authors:  Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-04

4.  Sudden unexpected death in dravet syndrome.

Authors:  Jennifer Kearney
Journal:  Epilepsy Curr       Date:  2013-11       Impact factor: 7.500

5.  Age-specific periictal electroclinical features of generalized tonic-clonic seizures and potential risk of sudden unexpected death in epilepsy (SUDEP).

Authors:  Joel Freitas; Gurmeen Kaur; Guadalupe Baca-Vaca Fernandez; Curtis Tatsuoka; Farhad Kaffashi; Kenneth A Loparo; Shyam Rao; Jakrin Loplumlert; Kitti Kaiboriboon; Shahram Amina; Ingrid Tuxhorn; Samden D Lhatoo
Journal:  Epilepsy Behav       Date:  2013-09-05       Impact factor: 2.937

6.  Randomized Controlled Trial of Melatonin for Sleep Disturbance in Dravet Syndrome: The DREAMS Study.

Authors:  Kenneth A Myers; Margot J Davey; Michael Ching; Colin Ellis; Bronwyn E Grinton; Annie Roten; Paul A Lightfoot; Ingrid E Scheffer
Journal:  J Clin Sleep Med       Date:  2018-10-15       Impact factor: 4.062

7.  Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.

Authors:  John C Oakley; Alvin R Cho; Christine S Cheah; Todd Scheuer; William A Catterall
Journal:  J Pharmacol Exp Ther       Date:  2013-02-19       Impact factor: 4.030

8.  Knock-in model of Dravet syndrome reveals a constitutive and conditional reduction in sodium current.

Authors:  Ryan J Schutte; Soleil S Schutte; Jacqueline Algara; Eden V Barragan; Jeff Gilligan; Cynthia Staber; Yiannis A Savva; Martin A Smith; Robert Reenan; Diane K O'Dowd
Journal:  J Neurophysiol       Date:  2014-05-07       Impact factor: 2.714

9.  Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome.

Authors:  Christine S Cheah; Frank H Yu; Ruth E Westenbroek; Franck K Kalume; John C Oakley; Gregory B Potter; John L Rubenstein; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

Review 10.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.